BRÈVE

sur Catheter Precision, Inc

Catheter Precision Secures First Purchase Order for LockeT from HCA Healthcare Facility

Catheter Precision, Inc. (NYSE American: VTAK), a prominent MedTech company noted for its cardiac electrophysiology products like VIVO™ and LockeT, has announced receiving its first purchase order for LockeT from an HCA Healthcare facility. HCA Healthcare, generating over $64 Billion in 2023, ranks among the top U.S. healthcare service providers, with a vast network of 186 hospitals across 20 states and the United Kingdom.

CEO David Jenkins expressed optimism about this development, highlighting the significance of LockeT's acceptance within HCA's regional medical centers. He indicated potential yearly usage of 1,000 devices across various specialties. Jenkins anticipates this initial purchase might lead to broader adoption among esteemed hospital groups, including teaching institutions, reflecting confidence in the value and effectiveness of their product.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Catheter Precision, Inc